Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Genetically-modified chickens offer hope for cheaper drugs
Chickens could be used as a cheaper method for producing high-quality research drugs.

New method produces therapeutic proteins as part of the egg white

Researchers at the University of Edinburgh’s Roslin Institute have genetically-modified chickens to produce human proteins in their eggs.

It is hoped the method could one day offer a cost-effective solution for producing certain drugs, including therapies for treating cancer.

The team found that high quantities of the proteins needed for the drugs could be recovered from each egg using a purification system. The drugs they recovered worked as well as if the same proteins were produced using existing methods.

Their findings suggest that chickens could be used as a cheaper method for producing high-quality research drugs. Looking ahead it is also hoped that the drugs could be used in patients.

The team set out to produce high-quality proteins for use in scientific research. They did not witness any adverse effects on the chickens themselves, which continued to lay eggs as normal.

Scientists already use eggs to produce vaccinations, such as the influenza vaccine. But the new method differs because the proteins are produced as part of the egg white.

In this study, three eggs were enough to develop a dose of the drug that is clinically relevant. With chickens laying up to around 300 eggs per year, researchers say the approach could be more cost-effective than current methods.

The two proteins the team have been focusing on are IFNalpha2a, which has powerful anti-cancer and anti-inflammatory effects, and macrophage-CSF, which can stimulate the repair of damaged tissues.

Professor Helen Sang of the Roslin Institute said: “We are not yet producing medicines for people, but this study shows that chickens are commercially viable for producing proteins suitable for drug discovery studies and other applications in biotechnology.”

Dr Lissa Herron, head of the Avian Biopharming Business Institute at Roslin Technologies, added: “We are excited to develop this technology to its full potential, not just for human therapies in the future but also in the fields of research and animal health.”

The findings are published in the journal BMC Biotechnology. 

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.